The Board

Johan Bygge

Chairman of the board

Chairman of the board since May 2021. Johan Bygge holds a Master of Science from Stockholm School of Economics.

Previous experience: Chairman of EQT Asia Pacific, COO EQT, CFO Investor AB, Deputy CEO Electrolux, CFO Electrolux. Board member of Anticimex, PSM Ltd, I-Med, ILA Vietnam, Sanitec Oy, Hi3G Scandinavia, Rådet för god sed på Aktiemarknaden, etc.

Other assignments: Chairman of the board of Scandi Standard AB (publ) and Yangi AB. Deputy chairman of the board of Tredje AP-fonden (AP3). Board member of Getinge AB, Capman Plc, Lantmännen ek för. SNS Förtroenderåd etc.

Shareholding: 6,286 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Göran Forsberg

Member of the board

Board member since May 2019. Born 1963. Göran Forsberg is a PhD in Biochemistry and Associate Professor.

Previous experience: Göran Forsberg has more than 30 years of experience from pharmaceutical development in both the Biotech industry and in large pharmaceutical companies. He has extensive experience of many different parts of drug development, as well as business development and investor relations. Göran Forsberg is the CEO of Cantargia AB since 2014. Prior to that, he worked as a business development manager at Active Biotech. Previous experience comes from positions at Pharmacia, KabiGen and the University of Adelaide in Australia and as Board member of Isogenica Ltd.

Other assignments: Göran Forsberg is CEO of Cantargia AB since 2014.

Shareholding: 1,369 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Johannes Hulthe

Member of the board

Board member since May 2019. Born 1970. Johannes Hulthe is a PhD and MSc in Economics.

Previous experience: Johannes Hulthe has more than 17 years of experience from the pharmaceutical industry. Lecturer in cardiovascular prevention at Sahlgrenska University Hospital, Gothenburg. Johannes Hulthe was under 13 years employed at AstraZeneca and, when he finished in 2014, held the role of chief (vice president) in clinical drug development for heart vessels, metabolism and kidney disease.

Other assignments: Co-founder, CEO and board member of Antaros Medical AB, board member of Antaros Holding AB, chairman of Antaros Renostic AB.

Shareholding: 6,000 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Lars Höckenström

Member of the board

Board member since October 2019. Born 1956. Lars Höckenström holds an MBA from Stockholm University.

Previous experience: Lars Höckenström has more than 35 years of finanical experience as an advisor in private and public transactions such as IPOs, rights issues and private placements within a broad range of sectors. Lars was a co-founder and Partner at Aragon Fondkommission AB, financial analyst at Öhman Fondkommission AB, Head of Research at Matthew Fondkommission AB, investment manager at Core Ventures, analyst and fund manager at Catella Kapitalförvaltning AB and analyst and corporate finance at Paretos Securities. He was also co-founder and Senior Advisor at Naventus Corporate Finance AB.

Other assignments: Board member of Devyser Diagnostics AB and AB Consiliario.

Shareholding: 800 shares

Independent in relation to the company and its senior management as well as to its major shareholders.